Introduction

This Statistical Brief provides descriptive statistics on expenditures for the top five therapeutic classes of outpatient prescription drugs in 2007 (ranked by total expenses) for adults age 18 and older in the U.S. civilian noninstitutionalized population. MEPS uses prescription drugs therapeutic classes as defined by the Multum Lexicon (see Definitions). In 2007, 17 broad therapeutic classes were identified.

The estimates presented are derived from the Household and Pharmacy Components of the 2007 Medical Expenditure Panel Survey. Expenditures include payments from all sources (e.g., out of pocket, private and public insurance sources) for outpatient prescription drug purchases during 2007. Insulin and diabetic supplies and equipment are also included in MEPS prescribed medicines estimates. Over-the-counter medicines are excluded from these estimates as are prescription medicines administered in an inpatient setting or in a clinic or physician’s office. All differences discussed in the text are statistically significant at the 0.05 level or better.

Findings

In 2007, the top five therapeutic classes of prescribed drugs purchased by adults age 18 and older (ranked by total expense) accounted for 62.1 percent of the $220.1 billion total prescription drug expenses by adults (figure 1).

Metabolic agents had the highest total expenses ($40.7 billion) among the top five therapeutic classes for adults age 18 and over (figure 2). The second through fifth highest therapeutic classes respectively in terms of total expenditures were central nervous system agents ($31.5 billion), cardiovascular agents ($28.9 billion), gastrointestinal agents ($18.3 billion), and psychotherapeutic agents ($17.2 billion). When expressed as percentages of all prescribed medicine expenses for adults, these classes ranged from 18.5 percent for metabolic agents to 7.8 percent for psychotherapeutic agents (figure 3).

Among adults with a prescribed drug expense (about two-thirds of population), 46.1 percent purchased central nervous system agents and 40.5 percent purchased cardiovascular agents (figure 4). The percentage who purchased metabolic agents (30.6 percent) was also higher than the percentage who purchased gastrointestinal agents (17.9 percent) or psychotherapeutic agents (16.7 percent).

In terms of average expense per prescription, gastrointestinal agents had the highest average ($121) and cardiovascular agents had the lowest average ($41) among the top five therapeutic classes (figure 5). Among the other three classes, the averages per prescription for metabolic agents and for psychotherapeutic agents (about $91 each) were higher than for central nervous system agents ($69).

Data Source

The estimates shown in this Statistical Brief are based on data from the MEPS HC-113: 2007 Full Year Consolidated Data File and the MEPS HC-110A: 2007 Prescribed Medicines.
Definitions

Therapeutic classifications
Therapeutic class and subclass were assigned to MEPS prescribed medicines using Multum Lexicon variables from Cerner Multum, Inc. MEPS prescribed medicines files were linked to the Multum Lexicon database to obtain therapeutic class and subclass variables.

Therapeutic class cardiovascular agents include calcium channel blockers and diuretics; central nervous system agents include the analgesics, anticonvulsants and antiparkinson agents. The therapeutic class of gastrointestinal agents includes the H2-receptor antagonists, antacids, antidiarrheals, and proton pump inhibitors; metabolic agents include the subclasses of antihyperlipidemic agents and antidiabetic agents; and psychotherapeutic agents include the subclass of antidepressants and antipsychotics.

Cerner Multum occasionally makes changes to the Multum Lexicon therapeutic classification system. For example, antihyperlipidemic agents was its own therapeutic class in the 2003 and 2004 data, but was reclassified as a therapeutic subclass of the new therapeutic class, metabolic agents, in 2005. These types of changes effect comparisons of the types of estimates presented in this Brief across years.

About MEPS-HC

MEPS-HC is a nationally representative longitudinal survey that collects detailed information on health care utilization and expenditures, health insurance, and health status, as well as a wide variety of social, demographic, and economic characteristics for the U.S. civilian noninstitutionalized population. It is cosponsored by the Agency for Healthcare Research and Quality and the National Center for Health Statistics.

For more information about MEPS, call the MEPS information coordinator at AHRQ (301) 427-1656 or visit the MEPS Web site at http://www.meps.ahrq.gov/.

References

For a detailed description of the MEPS-HC survey design, sample design, and methods used to minimize sources of nonsampling error, see the following publications:


Suggested Citation


* * *

AHRQ welcomes questions and comments from readers of this publication who are interested in obtaining more information about access, cost, use, financing, and quality of health care in the United States. We also invite you to tell us how you are using this Statistical Brief and other MEPS data and tools and to share suggestions on how MEPS products might be enhanced to further meet your needs. Please e-mail us at mepspd@ahrq.gov or send a letter to the address below:

Steven B. Cohen, PhD, Director
Center for Financing, Access, and Cost Trends
Agency for Healthcare Research and Quality
540 Gaither Road
Rockville, MD 20850
Figure 1. Expenditures for top five therapeutic classifications of prescribed drugs relative to total prescription medication expenses, adults age 18 and older, 2007

Total RX Expenditures = $220.1 billion

$83.4 billion

$136.7 billion

Source: Center for Financing, Access, and Cost Trends, AHRQ, Household and Pharmacy Components of the Medical Expenditure Panel Survey, 2007

Figure 2. Total expenses for prescribed drugs by therapeutic classifications (top five), adults age 18 and older, 2007

Source: Center for Financing, Access, and Cost Trends, AHRQ, Household and Pharmacy Components of the Medical Expenditure Panel Survey, 2007
Figure 3. Expenditures for top five therapeutic classifications as percentages of total prescription medication expenses, adults age 18 and older, 2007

<table>
<thead>
<tr>
<th>Therapeutic Classification</th>
<th>Percentage of Total RX Expenses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic agents</td>
<td>18.5</td>
</tr>
<tr>
<td>Central nervous system agents</td>
<td>14.3</td>
</tr>
<tr>
<td>Cardiovascular agents</td>
<td>13.2</td>
</tr>
<tr>
<td>Gastrointestinal agents</td>
<td>8.3</td>
</tr>
<tr>
<td>Psychotherapeutic agents</td>
<td>7.8</td>
</tr>
</tbody>
</table>

Source: Center for Financing, Access, and Cost Trends, AHRQ, Household and Pharmacy Components of the Medical Expenditure Panel Survey, 2007

Figure 4. Percentage of adults with prescribed drug expenses by therapeutic classification (top five), adults age 18 and older with prescribed medication expenses, 2007

<table>
<thead>
<tr>
<th>Therapeutic Classification</th>
<th>Percentage of Adults with RX Expense</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic agents</td>
<td>30.6</td>
</tr>
<tr>
<td>Central nervous system agents</td>
<td>46.1</td>
</tr>
<tr>
<td>Cardiovascular agents</td>
<td>40.5</td>
</tr>
<tr>
<td>Gastrointestinal agents</td>
<td>17.9</td>
</tr>
<tr>
<td>Psychotherapeutic agents</td>
<td>16.7</td>
</tr>
</tbody>
</table>

Source: Center for Financing, Access, and Cost Trends, AHRQ, Household and Pharmacy Components of the Medical Expenditure Panel Survey, 2007
Figure 5. Average expense per prescription by therapeutic classification (top five), adults age 18 and older, 2007

Source: Center for Financing, Access, and Cost Trends, AHRQ, Household and Pharmacy Components of the Medical Expenditure Panel Survey, 2007